Ruthenium (II)/amino acid/diphosphine complexes as apoptosis inducers in breast cancer cells and their toxic effects in animal models.

Cytotoxicity and mechanism of action of ruthenium(II)/amino acids/diphosphine complexes were evaluated against breast cancer (MDA-MB-231 cells), as well as their toxic effects in animal models.

 

Ruthenium (II)/amino acid/diphosphine complexes as apoptosis inducers in breast cancer cells and their toxic effects in

animal models.

Francyelli Mello-Andrade1,2, Clever G. Cardoso3, Paulo Melo-Reis4, Cesar Grisólia5, Carlos Castro6, Carlos Menck7, Alzir A.

Batista8, Elisângela Silveira-Lacerda1,2.

1 Laboratório de Oncologia Experimental, Instituto de Física, UFG;

2 Departamento de Genética, Instituto de Ciências Biológicas, UFG;

3 Departamento de Histologia, Embriologia e Biologia Celular, Instituto de Ciências Biológicas, UFG;

4 Departamento de Biomedicina, PUCGO;

5 Departamento de Genética e Morfologia, UnB;

6 Departamento de Fisiologia, Instituto de Ciências Biológicas, UFG;

7 Departamento de Microbiologia, Instituto de Ciências Biomédicas, USP;

8 Departamento de Química, UFSCar.

Cytotoxicity and mechanism of action of ruthenium(II)/amino acids/diphosphine complexes were evaluated against breast

cancer (MDA-MB-231 cells), as well as their toxic effects in animal models. The cell death type induced in MDA-MB-231

cells by compounds was evaluated measuring Annexin V-positive number, the activated caspases levels, and by morphological

features. In order to clarify which mechanisms are responsible for led breast cancer cells to death, we evaluated whether these

compounds can cause DNA damage, changes in cell cycle kinetic, mitochondrial dysfunction, and ultrastructural alterations in

MDA-MB-231 cells. As toxicity assessment is a required step for preclinical study of novel metal based compounds, the acute

oral toxicity was evaluated, and the genetic toxicity was determined by Micronucleus (MN) and Comet assay protocols on

Swiss mice treated with these complexes. Zebrafish model was used to evaluate toxicity of Ru(II)/amino acids complexes

during embryonic and larval development, more specifically, the mortality and hatching rates of zebrafish were determined.

Ru(II)/amino acids complexes induced apoptosis in MDA-MB-231 cells by increase in number of Annexin V-positive cells,

morphological changes, loss of mitochondrial membrane potential, and caspases-3 and 7 activation. Although these

compounds have a weak interaction to DNA molecule, it was observed DNA damage, probably due to reactive oxygen species

production related to mitochondrial membrane depolarization. As can be seen by ultrastructural analysis, these complexes can

reduce mitochondrial amount in MDA-MB-231 cells. Thus, Ru(II)/amino acids complexes are more active for tumor cells, and

their mechanism of action are related to induction cell cycle block, DNA damage, and mitochondrial dysfunction, lead to

apoptosis involving p53, PARP cleavage and caspases activation. In addition, these compounds were very well tolerated orally,

and it was observed lack of micronuclei formation in bone marrow cells and low DNA damage in peripherical blood cells from

Swiss mice. As regard to toxicity on zebrafish embryo development, the compounds caused low embryotoxicity, being mainly

observed hatching delay and mortality at high concentrations. Altogether our findings suggest that ruthenium (II)/amino

acids/diphosphine complexes induce cellular and molecular responses in breast cancer cells leading to mitochondria-mediated

apoptosis, and they are not harmful, presenting low systemic toxic effects.

Key words: ruthenium, preclinical tests, side-effects, apoptosis, ROS.